Inventiva Expands Its Share Offering in the United States
The biopharmaceutical company Inventiva has announced that the bookrunners have exercised their option to subscribe for additional shares as part of its public offering in the United States.
Full Exercise of Subscription Option
According to the press release, Inventiva saw the bookrunners associated with the public offering in the United States fully exercise their option to subscribe to an additional 5,844,155 American Depositary Shares, each representing one ordinary share of the company. This brings the total number of ADS issued in the offering to 44,805,193, for a gross amount of approximately $172.5 million, equivalent to about €149.0 million. The net proceeds from the offering, after deducting fees and commissions, are estimated at $161.2 million, or €139.3 million.
Utilization of Net Proceeds
Inventiva plans to use the net proceeds from the offering of the new ADS proportionally to the intended use outlined in the initial offering. The subscription price was set at $3.85 per ADS, equivalent to €3.33 per ordinary share, at a discount to the average volume-weighted price of the share on Euronext. This price was validated by the CEO, under delegation from the Board of Directors, in accordance with the resolutions of the mixed general meeting on May 22, 2025.
Regulatory Filings
The company has filed the Form F-3 document with the U.S. SEC, which became effective on November 3, 2025. Although the offer does not require the approval of the French Financial Markets Authority, Inventiva has filed an information document with the AMF due to a dilution exceeding 30% of its current share capital. This document is available on the company's website.
